Long COVID and ME/CFS can affect patients in very different ways, despite being grouped under the same diagnostic labels. Different combinations of genes, biological mechanisms, and symptoms may contribute to that variation, creating challenges for research, clinical trials, and treatment development. In this episode of Biology Matters: Solving Chronic Disease, PrecisionLife Co-Founders Steve Gardner and Rowan Gardner reflect on five years of research into long COVID and ME/CFS. They discuss what genetic research is revealing about the biology of these conditions, the overlap between long COVID and ME/CFS, the importance of patient involvement, and why understanding biological subgroups could support more targeted clinical research. The conversation also explores how these research findings are beginning to be translated into patient-facing biological insight, including through PrecisionLife’s Post COVID DNA Wellness Report, which is intended for general wellness and educational purposes. If you or someone you know is experiencing long COVID, learn more about the Post COVID DNA Wellness Report here: https://precisionlife.com/longcovid The Post COVID DNA Wellness Report provides general wellness and educational information based on findings from PrecisionLife’s long COVID research. It is not a diagnostic or clinical test and does not provide medical advice.

If we can understand which biological mechanisms are driving different outcomes in different patients, how much more precise could medicine become? Take GLP-1 therapies, for example. They’re reshaping the treatment of metabolic disease, but they do not work the same way for every patient. In this episode of Biology Matters, Barry Wark, Co-Founder and Chief Strategy Officer of Ovation, breaks down why the next phase of precision medicine may depend on linking multi-omic data with longitudinal clinical outcomes. Together, they explore how real-world patient data can help researchers understand who responds to therapies, why different outcomes may be driven by different biological mechanisms and how more focused datasets could support better clinical trials, smarter payer decisions and faster translation of new insights into healthcare.

ME/CFS and Long COVID are complex, multi-system conditions that have been difficult to diagnose, study and treat through traditional approaches. Yet standard trials keep failing because they treat heterogeneous patient cohorts as a single disease. In this episode of Biology Matters, PrecisionLife CEO Steve Gardner joins Chris Armstrong, Director of the Melbourne ME/CFS Collaboration and Scientific Advisor to the Open Medicine Foundation. Together, they explore how mechanistic patient stratification can break the deadlock in developing successful treatments for chronic complex diseases like long COVID and ME/CFS.

Women’s health is often discussed through the narrow lens of reproductive health. But the real scope of women’s health is much broader than that. In this episode of Biology Matters, host Rowan Gardner, Co-Founder of PrecisionLife, speaks with Chief Medical Officer, Dr. Veronique Bouchet, about why women’s health must be understood across the full spectrum of complex chronic disease. They explore why conditions ranging from cardiovascular disease and autoimmune disease to migraines, Alzheimer’s disease, and endometriosis require deeper biological understanding, better research, earlier diagnosis and more precise treatment pathways. Our healthcare systems are often working with incomplete data and this contributes to diagnostic delays. Could precision medicine help clinicians, patients, researchers, pharma and investors move toward better outcomes? Tune in to find out.

Myalgic encephalomyelitis, also called chronic fatigue syndrome or ME/CFS, affects an estimated 17 – 24 million people worldwide, with many more experiencing ME-like symptoms after infections such as COVID. So, why does the disease remain poorly understood, difficult to diagnose and deeply isolating? In this episode of Biology Matters, host Steve Gardner speaks with Sonya Chowdhury, CEO of Action for ME, about why ME/CFS has remained invisible for so long, how patient advocacy is helping move research, policy and clinical understanding forward and why better funding, better diagnostics and precision medicine could help shift the field from recognition to real treatment options.

Healthcare systems all around the world are under pressure, and the common denominator is chronic disease. In this episode of Biology Matters, Ray Pawlicki, Executive Chairman at PrecisionLife, and host Steve Gardner explore how a shift from reacting to illness toward diagnosing, treating, and preventing disease much earlier is the solution we need to relieve this pressure. Drawing on decades of leadership experience across Novartis, Biogen, UMass Memorial Health, and beyond, Ray explains why technology is now a strategic priority in healthcare, why culture matters just as much as data, and why solving chronic disease will require new thinking on the part of providers, payers, patients, and healthcare leaders alike.

Healthcare systems around the world are under growing pressure from aging populations, rising costs, and the increasing burden of chronic disease. In the debut episode of Biology Matters, hosts Steve and Rowan Gardner, co-founders of PrecisionLife, explore why many complex diseases remain so difficult to understand and treat and the merit in answering the question, “How do we prevent people from falling sick? ”. This conversation reveals how advances in biology, data, and precision medicine could help healthcare move toward earlier prediction, more personalized treatment, and better prevention because building healthier futures demands that science, healthcare, and society completely rethink how we understand disease.

Biology Matters is a podcast about one of the biggest challenges facing modern healthcare: chronic disease. These conditions affect billions of people, account for the majority of healthcare spending, and yet remain poorly understood, difficult to diagnose, and often ineffective to treat. The result is not just a scientific problem, but a system-wide healthcare crisis. Hosted by Steve and Rowan Gardner of PrecisionLife, the podcast takes a different approach - starting with biology. Through conversations with healthcare executives, researchers, biotech leaders and patient advocates, Biology Matters explores how a deeper, mechanism-based understanding of disease can transform how we predict risk, stratify patients, and make better clinical and development decisions. Each episode connects biological insight to real-world impact - from improving patient outcomes and reducing system inefficiencies, to enabling more successful clinical trials and more precise treatment strategies. If healthcare is to move from reactive treatment to predictive, preventative, and personalized care, it will require a fundamental shift in how we understand disease. This podcast is about what that shift looks like - and what it will take to make it happen.